Our Mission
CardiOmix seeks partners to support and participate in research and development associated with systems biology and translational medicine projects aimed at the integration of genetic, functional genomics, and clinical data to disentangle the molecular bases of serious and rare cardiovascular diseases.
It aims, through this effort, to achieve the more ambitious goal of linking clinical electrophysiological observables obtained from patients and healthy subjects with OMICS data by combining genomics analyses, machine learning, and artificial intelligence approaches, to uncover the underlying molecular dysregulations, and genomic structural variations underpinning Brugada and other sudden cardiac death syndromes.
Our Story
In their collaborative work, the founders of CardiOmix, Carlo Pappone, Luigi Anastasia, and Enrico Petretto established convincing evidence that the genetic background (phenotype) of an individual serves as a main determinant of epicardial electrophysiological abnormalities. Carriers of certain particular mutations exhibit more pronounced aberrations together with a more aggressive presentation. Thus, the blood relatives of patient who has been diagnosed with a life-threatening arrhythmogenic cardiomyopathy or has suffered a sudden cardiac death face an increased risk of cardiac arrest. This added risk calls for the medical examination and screening of all family members genetically associated with an acute cardiac episode. Unfortunately, many cases of electrophysiological abnormalities do not manifest in non-invasive electrocardiographic diagnoses.
Cardiomix argues that genomic information, in concert with epigenomic signs manifested in transcriptomic, proteomic and metabolomic biomarkers, can add significantly to the effectiveness of clinical diagnosis and cardiological risk stratification. The principal investigators of the research that has established this finding started Cardiomix with the aim of forming commercial alliances that will make biomarker diagnosis broadly available to persons at risk of sudden cardiac death throughout the world.